Tocqueville Asset Management L.P. Has $5.39 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Tocqueville Asset Management L.P. decreased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 28.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 54,716 shares of the biopharmaceutical company’s stock after selling 21,745 shares during the quarter. Tocqueville Asset Management L.P. owned 0.05% of Alnylam Pharmaceuticals worth $5,389,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Robeco Institutional Asset Management B.V. acquired a new position in Alnylam Pharmaceuticals in the first quarter valued at $170,000. Mutual of America Capital Management LLC boosted its stake in shares of Alnylam Pharmaceuticals by 98.5% during the second quarter. Mutual of America Capital Management LLC now owns 1,935 shares of the biopharmaceutical company’s stock worth $191,000 after buying an additional 960 shares during the period. IPG Investment Advisors LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $217,000. Riverhead Capital Management LLC raised its holdings in Alnylam Pharmaceuticals by 195.6% during the second quarter. Riverhead Capital Management LLC now owns 2,365 shares of the biopharmaceutical company’s stock worth $233,000 after purchasing an additional 1,565 shares in the last quarter. Finally, Commerzbank Aktiengesellschaft FI purchased a new position in Alnylam Pharmaceuticals during the second quarter worth about $240,000. 93.36% of the stock is currently owned by institutional investors.
In other news, COO Yvonne Greenstreet sold 2,500 shares of the business’s stock in a transaction dated Thursday, August 30th. The shares were sold at an average price of $120.00, for a total value of $300,000.00. Following the completion of the sale, the chief operating officer now owns 1,916 shares of the company’s stock, valued at approximately $229,920. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Laurie Keating sold 1,563 shares of the business’s stock in a transaction dated Wednesday, June 20th. The stock was sold at an average price of $105.04, for a total transaction of $164,177.52. Following the completion of the sale, the senior vice president now directly owns 16,063 shares of the company’s stock, valued at approximately $1,687,257.52. The disclosure for this sale can be found here. Insiders sold a total of 54,063 shares of company stock valued at $5,733,678 in the last three months. Insiders own 4.30% of the company’s stock.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.74) by $0.11. Alnylam Pharmaceuticals had a negative net margin of 533.52% and a negative return on equity of 38.09%. The firm had revenue of $29.91 million for the quarter, compared to the consensus estimate of $16.96 million. During the same quarter in the previous year, the firm posted ($1.07) EPS. The firm’s quarterly revenue was up 87.8% on a year-over-year basis. research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -7.27 earnings per share for the current year.
ALNY has been the subject of several analyst reports. Jefferies Financial Group reissued a “buy” rating and set a $149.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, August 6th. JMP Securities set a $198.00 price target on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 28th. Piper Jaffray Companies reaffirmed an “overweight” rating on shares of Alnylam Pharmaceuticals in a report on Monday, July 23rd. BidaskClub cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, June 18th. Finally, Goldman Sachs Group cut shares of Alnylam Pharmaceuticals from a “conviction-buy” rating to a “buy” rating in a report on Monday, August 13th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $145.55.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
Featured Article: Growth Stocks
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.